C-Met Signaling as a Therapeutic Target in Head and Neck Cancer

Sara M. Centuori, Julie E. Bauman

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Despite a dearth of activating driver mutations in head and neck squamous cell carcinoma (HNSCC), aberrant activation of the oncogenes, epidermal growth factor receptor (EGFR), and c-Met is near-universal in human papillomavirus (HPV)-negative disease. Although EGFR activation drove the successful development of the anti-EGFR monoclonal antibody cetuximab in HNSCC, no c-Met-targeting therapy has gained regulatory approval. Inhibition of the c-Met pathway may subvert oncogenesis within the tumor-intrinsic compartment, blocking tumoral proliferation, invasion, migration, and metastasis, or the tumor-extrinsic compartment, modulating the immunosuppressive tumor microenvironment. This review discusses the rationale and current drug development strategies for targeting c-Met or its exclusive ligand hepatocyte growth factor (HGF) in HNSCC.

Original languageEnglish (US)
Pages (from-to)346-353
Number of pages8
JournalCancer Journal
Issue number5
StatePublished - Sep 1 2022
Externally publishedYes


  • HGF
  • c-Met
  • head and neck squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'C-Met Signaling as a Therapeutic Target in Head and Neck Cancer'. Together they form a unique fingerprint.

Cite this